gerasa 100 mg gastrorezistentné tablety
g.l. pharma gmbh, rakúsko - kyselina acetylsalicylová - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
aggrenox, 200/25 mg tvrdé kapsuly s riadeným uvoľňovaním
boehringer ingelheim international gmbh, nemecko - antiagreganciá trombocytov okrem heparínu, kombinácie - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
acylcoffin
sanofi-aventis slovakia s.r.o. - kyselina acetylsalicylová, kombinácie s výnimkou psycholeptík - 07 - analgetica, antipyretica
alnagon neo
zentiva a.s., slovensko - kyselina acetylsalicylová, kombinácie s výnimkou psycholeptík - 07 - analgetica, antipyretica
plavix
sanofi winthrop industrie - klopidogrel hydrogénsulfát - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antitrombotické činidlá - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevencia atherothrombotic a thromboembolic udalosti v fibrilácia fibrillationin dospelých pacientov s fibrilácia predsiení, ktorí majú aspoň jeden rizikový faktor cievnych udalosti, nie sú vhodné na liečbu s vitamínom-k antagonisty a ktorí majú nízke riziko krvácania, klopidogrel, je indikovaná v kombinácii s asa pre prevenciu atherothrombotic a thromboembolic udalosti, vrátane mŕtvica.
stadapyrin 100 mg
stada arzneimittel ag, nemecko - kyselina acetylsalicylová - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
vasopirin 100 mg
bausch health ireland limited, Írsko - kyselina acetylsalicylová - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
abrea 100 mg
krka, d.d., novo mesto, slovinsko - kyselina acetylsalicylová - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
abrea 75 mg
krka, d.d., novo mesto, slovinsko - kyselina acetylsalicylová - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
abrea 160 mg
krka, d.d., novo mesto, slovinsko - kyselina acetylsalicylová - 16 - anticoagulantia (fibrinolytica, antifibrinol.)